Dimension Therapeutics Profile

5.95
USD 0.00  0.00%
0%
0%

Disposition of 32069 shares by Georges Gemayel of Dimension Therapeutics subject to Rule 16b-3

Dimension Therapeutics insider trading alert for disposition of stock option (right to buy) by Georges Gemayel, the corporate stakeholder, on June 14, 2018. This event was filed by Dimension Therapeutics In with SEC on 2017-11-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Dimension Therapeutics Summary

Dimension Therapeutics (DMTX) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 53 people. Dimension Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 149.97 M. Dimension Therapeutics has 25.21 M outstanding shares of which 167.31 K shares are currently shorted by private and institutional investors with about 4.13 trading days to cover. Dimension Therapeutics currently holds about 47.49 M in cash with (55.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.9.
Check Dimension Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 5.95HorizonTargetOdds Above 5.95
?%30 days 5.95 ?%
Based on normal probability distribution, the odds of Dimension Therapeutics to move above current price in 30 days from now is about 0.0% (This Dimension Therapeutics probability density function shows the probability of Dimension Therapeutics Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Orbimed Advisors LlcCommon Shares5.4 M32.4 M
Fmr LlcCommon Shares4.9 M29.4 M
View Dimension Therapeutics Diagnostics

Selected Dimension Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Earning Before Interest and Taxes USD    

Key Fundamentals

Dimension Therapeutics Against Markets

Current Ratings

Dimension Therapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
2 
Equity ratings for Dimension Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Dimension Therapeutics, Inc., a gene therapy platform company, focuses on discovering and developing therapeutic solutions for people living with rare diseases associated with the liver and caused by genetic mutations. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameDimension Therapeutics
CEO and President and DirectorMRCP MBBSView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationMASSACHUSETTS, U.S.A
Business AddressDimension Therapeutics, Inc.Cambridge, MA
ExchangeNASDAQ
CIK Number01592288.0
CUSIP25433V105
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.dimensiontx.com
Contact Number617 401 0011
CurrencyUSD - US Dollar

Recommendations

Dimension Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
16.33Buy3Odds
Dimension Therapeutics current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Dimension Therapeutics Analyst Advice  

Directors

Dimension Therapeutics Corporate Directors
Michael Dybbs Independent Director, Ph.D
George Migausky Independent Director, MBA
Georges Gemayel Independent Director, Ph.D
Additionally see Investing Opportunities. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.